questionText: To ask the Secretary of State for Health and Social Care, when NICE last reviewed its guidance on the (a) availability and (b) prescribing of T3 for the treatment of thyroid cancer; and whether he has plans to improve access to T3 for patients where it is clinically indicated.
answerText: The National Institute for Health and Care Excellence (NICE) has not made any recommendations on the use of liothyronine in the treatment of thyroid cancer. NICE published a guideline on the assessment and management of thyroid cancer in December 2022. Th...
heading: Thyroid Cancer: Liothyronine